Viking Therapeutics, Inc. VKTX R3KPHARMA
Company Overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -18.39% |
| 6 Months: | +0.21% |
| 3 Months: | +15.18% |
| 1 Month: | -1.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VKTX Viking Therapeutics, Inc. R3KPHARMA | 33.68 | -7.21 | $3.93B | 0.00% | -61.55% | -88.85% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.57M | 98.56M | 164.74M | 164.12M | 132.60M |
| Operating Income | -209.74K | -21.76M | -1.15M | -461.04K | -2.63M | -4.29M | -3.27M | -3.58M | -3.26M | -4.97M | -4.98M | -4.69M | -4.80M | -6.92M | -7.39M | -6.81M | -9.57M | -7.44M | -10.95M | -10.61M | -9.84M | -14.23M | -15.54M | -13.40M | -16.25M | -17.63M | -16.20M | -20.54M | -23.74M | -27.27M | -34.07M | -34.05M | -36.56M | - | - | -74.57M | -98.56M | -164.74M | -164.12M | -132.60M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -74.46M | -98.45M | -164.64M | -164.04M | -132.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -65.56M | -90.79M | -157.66M | -158.32M | -128.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -228.94K | -22.78M | -261.80K | -5.71M | -7.87M | -4.74M | -3.59M | -3.69M | -3.81M | -5.22M | -5.17M | -6.10M | -3.55M | -6.67M | -6.60M | -4.92M | -7.67M | -5.73M | -9.69M | -9.57M | -9.29M | -14.01M | -15.38M | -13.24M | -16.10M | -17.43M | -15.77M | -19.53M | -19.23M | -22.53M | -27.36M | -22.25M | -24.94M | - | - | -65.56M | -90.79M | -157.66M | -158.32M | -128.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.23 | - | - | -0.10 | - | - | -0.07 | - | - | - | - | - | - | -0.20 | -0.17 | -0.21 | -0.23 | -0.21 | -0.25 | -0.19 | -0.23 | -0.26 | -0.20 | -0.22 | - | - | -0.58 | -0.81 | -1.38 | -1.37 | -1.10 |
| R&D Expense | 50.00K | 21.24M | 788.65K | 138.97K | 1.10M | 2.51M | 1.88M | 2.37M | 2.10M | 3.53M | 3.72M | 3.46M | 3.04M | 5.22M | 5.69M | 4.50M | 7.33M | 5.28M | 7.99M | 7.78M | 7.12M | 11.54M | 12.80M | 10.79M | 12.55M | 13.54M | 11.96M | 11.01M | 13.92M | 18.38M | 24.10M | 23.77M | 22.79M | - | 41.39M | 60.15M | 89.95M | - | 150.15M | 115.75M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 70.36M | 100.83M | 150.92M | 393.34M |
| Operating Income | -23.47M | -12.00M | -13.85M | -19.07M | -26.16M | -32.69M | -42.66M | - | -70.36M | -100.83M | -150.92M | -393.34M |
| EBITDA | - | - | - | - | - | - | - | - | -70.06M | -100.53M | -150.57M | -392.91M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | -68.87M | -85.89M | -109.96M | -359.64M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -21.88M | -23.40M | -14.73M | -20.58M | -22.06M | -25.78M | -39.49M | - | -68.87M | -85.89M | -109.96M | -359.64M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.90 | -0.91 | -1.01 | -3.19 |
| R&D Expense | 22.22M | 6.97M | 9.00M | 13.74M | 19.04M | 23.56M | 31.93M | 44.98M | 54.23M | 63.81M | 101.64M | 344.95M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.04M | 15.44M | 14.54M | 22.12M | 302.31M | 284.26M | 256.50M | 210.66M | 168.53M | 368.49M | 908.32M | 715.73M |
| Current Assets | - | - | - | - | - | - | - | - | - | 167.04M | 367.23M | 907.22M | 715.60M |
| Cash & Equivalents | 179.62K | 755.86K | 768.55K | 3.08M | 8.99M | 24.78M | 8.38M | 29.12M | 26.37M | 36.63M | 55.52M | 26.68M | 165.81M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 25.17M | 6.71M | 6.49M | 8.66M | 4.56M | 7.14M | 12.16M | 8.78M | 23.21M | 20.07M | 28.04M | 76.67M |
| Current Liabilities | - | 22.52M | 1.98M | 6.48M | 8.66M | 4.55M | 6.78M | 12.13M | 8.78M | 21.95M | 19.14M | 27.41M | 76.67M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 1.56M | 1.26M | 1.12M | 137.00K |
| Total Equity | -250.60K | -22.13M | 8.72M | 8.04M | 13.46M | 297.75M | 277.12M | 244.34M | 201.88M | 145.32M | 348.42M | 880.28M | 639.06M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 80.45M | 102.31M | 111.57M | 114.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -14.76M | -18.75M | -24.75M | -21.78M | - | -48.40M | -73.38M | -87.79M | -278.69M |
| Investing Cash Flow | - | - | - | -1.73M | -265.73M | 7.46M | 41.57M | - | 54.75M | -179.09M | -553.37M | 341.39M |
| Financing Cash Flow | - | - | - | 22.40M | 300.27M | 887.00K | 950.00K | - | 4.16M | 271.38M | 612.46M | 76.44M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | -48.40M | -73.38M | -87.79M | -278.69M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 10.52M | 18.91M | -28.69M | 139.14M |
| Share Buybacks | 2 | 38 | 229 | - | - | - | - | - | 6.79M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 98.9% | -268.2% | -183.2% | -152.8% | -7.4% | -9.3% | -16.2% | - | -47.4% | -24.7% | -12.5% | -56.3% |
| ROCE % | 120.5% | -89.1% | -171.8% | -141.6% | -8.8% | -11.8% | -17.5% | - | -48.0% | -28.9% | -17.1% | -61.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 5.43% | 6.34M | $183.67M |
| 2 | Blackrock Inc. | 5.31% | 6.19M | $179.44M |
| 3 | State Street Corporation | 4.81% | 5.61M | $162.53M |
| 4 | Vanguard Capital Management LLC | 4.33% | 5.05M | $146.51M |
| 5 | Vanguard Portfolio Management LLC | 3.84% | 4.48M | $130.00M |
| 6 | Two Sigma Investments, LP | 3.38% | 3.94M | $114.15M |
| 7 | Morgan Stanley | 2.99% | 3.49M | $101.06M |
| 8 | Ameriprise Financial, Inc. | 1.85% | 2.16M | $62.50M |
| 9 | Geode Capital Management, LLC | 1.80% | 2.10M | $60.82M |
| 10 | American Century Companies Inc | 1.56% | 1.82M | $52.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VKTX
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE1KcVZIMnNCTnpOQUtncDhoRVptaGFyNFV5RGlWRDVsOTNlWUlPQlJUWjNpQ0JQRnhGMXR5cmNPWkNjUi03LUZyNjFsbTJhZw?oc=5" target="_blank">Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & H…
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOUDVESTFyRWx2T1FKVVFTU01EaTRfcDV5U3lXR0ZJdG1IMUxrSmVtdVV2X0d2MGd6eklVaGdpSDRvV0ZTdmdWQUZVZTNWVVkwLXd0MU1UUzJaZG1scTJMbGg0M0xNOERacUdxajBjb2c1UDg3YUhMT2FUZ0R3Y01nTUJ4LVFua294Qzh4bE…
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZzh2bE5ZNzZ5VjVHMlFlVHRCSkRuUld3bDFWaVh1UjFFczJ1Ny1SMkp2SllhdC1yMXVzZ3cwTXgwQmcyMlhmVFJWUGRJTXcxYVl6ZHZ3MDQ5eVhnRUdseUh2bnUtUHJ0Uml1MndKdkN1a2pZcVFfYnhaN1c0enY5TUhQa2lKVUZrUi04Vl…
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQNzR3UDloSVJaalp4cXFKdWFzeVNrRU5hTkZzRTZza3hhWXg3MGJVejM0OEUwbzlGSzZMRkVKOEhQREpPQ2FWcFMzdUp6WkRqMnFoWVNBMzcyRjFycmRvZHFBUjRUMDZNX2stQ2RxbkZpYkszalN6S3BiWTJqclpTLWlTWmZFT1plNWxKTE…
Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQOTUyc2pxa183TFRYV1A5QlZGYzVMQmpzSmJSaU1ORjdsS1d2dzhNS3ozNGFPeG83c1BfYkJfN05JQ3l6aGl5NEVqeUpKeXRoTmNlWDVRYS1GaVZMSU4zX2tZcktlWmhDcmE3OVAxZ1NfTjk1czVMYVJRZGlXMTZON3otUmpQdnBjc3Nwbm…
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNRVZUcVdaSEtWZ0YtREhhd1ZMV0ZuMEp6aERCQlA2Nm5WSUZDQ2J1ZW8xbHdKamxYcTFfcGE3b1lRQ1YxQ1BDRWVPVm5NRFh5cGhlUFFGbThUVW1WTFVBYUZrWWJVSzRCVU9tMXVCSGxsOEJRNko5MzhuQl9tUHhsQlJKd1hUTU9LM2NIZD…
VKTX — Frequently Asked Questions
What is the current share price of Viking Therapeutics, Inc. (VKTX)?
As of 2026-09-19 21:16 PDT, Viking Therapeutics, Inc. (VKTX) trades at $33.68 on NasdaqCM. Its 52-week range is $23.09 to $42.13.
What is the market capitalisation of VKTX?
Viking Therapeutics, Inc. (VKTX) has a market capitalisation of $3.93B on NasdaqCM.
What is the P/E ratio of VKTX?
VKTX trades at a trailing price-to-earnings (P/E) ratio of -7.21. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.28.
What is the return on equity (ROE) of VKTX?
VKTX has a return on equity (ROE) of -88.85%. Its return on capital employed (ROCE) is -61.55%.
Is VKTX a good stock to buy?
This page provides a data-driven analysis of Viking Therapeutics, Inc. (VKTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.